Evidence map›Paper›PMID 26692682›Full record

ArticleUrology annals

Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature.

Munad Khan, Nieroshan Rajarubendra, Sarah Azer, Alison Skene, Simon J Harrison, Belinda Campbell, Nathan Lawrentschuk

Abstract readCase Reports
In one paragraph

Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Munad KhanDepartment of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.
Nieroshan RajarubendraDepartment of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.
Sarah AzerDepartment of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia.
Alison SkeneDepartment of Pathology, Austin Hospital, Melbourne, Australia.
Simon J HarrisonDepartment of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia ; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia.
Belinda CampbellDepartment of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia ; Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Nathan LawrentschukDepartment of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia ; Olivia Newton-John Cancer Research Department, Austin Hospital, Melbourne, Australia ; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testicular plasmacytoma, whether occurring as a primary lesion or as a reflection of underlying multiple myeloma (MM), is a rare disease. We report the case of a 38-year-old male with multiply relapsed MM, who was found to have a testicular plasmacytoma. He presented with a gradually enlarging scrotal mass. Following orchidectomy, pathologic examination of the specimen demonstrated a plasmacytoma. In the context of active MM, the specimen was also sent for cytogenetic analysis but this was unhelpful in guiding a chemotherapy regime, which still continues at time of reporting. Although a rare lesion, there remains no definitive treatment protocol for the management of testicular plasmacytoma representing an extramedullary manifestation of MM.

Indexed as

Extramedullary plasmacytomamultiple myelomaplasmacytomatestis

Identifiers

PMID26692682
PMCPMC4660713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.